Puma Biotechnology Inc (PBYI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $401.70M
Last updated: Nov 17, 2026 at 11:06 AM ET
Puma Biotechnology Inc (PBYI) Earnings: Report Dates and Results
Puma Biotechnology (PBYI) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Puma Biotechnology reported EPS of $0.11, above the $0.06 estimate. It beat the EPS estimate in each of the last 11 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PBYI has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 11.5% below the $0.26 reported for the quarter ended Dec 31, 2025.
PBYI Earnings Call
The latest PBYI earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, PBYI beat 32 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $55.06M, up 1.1% from $54.48M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.11 | $0.06 | N/A | +83.33% | Beat | -47.6% | 1 | 0 up, 0 down | Nov 5, 2026 | $55.06M |
| Jun 30, 2026 | $0.16 | $0.06 | N/A | +166.67% | Beat | +33.3% | 1 | 0 up, 0 down | Aug 6, 2026 | $56.50M |
| Mar 31, 2026 | -$0.04 | -$0.13 | -$0.13 - -$0.13 | +69.23% | Beat | -166.7% | 1 | 0 up, 0 down | May 7, 2026 | $44.81M |
| Dec 31, 2025 | $0.26 | $0.19 | N/A | +36.84% | Beat | -39.5% | 1 | 1 up, 0 down | Feb 26, 2026 | $75.45M |
| Sep 30, 2025 | $0.21 | $0.09 | $0.09 - $0.09 | +133.33% | Beat | -53.3% | 1 | 0 up, 1 down | Nov 6, 2025 | $54.48M |
| Jun 30, 2025 | $0.12 | $0.08 | N/A | +50.00% | Beat | N/A | 1 | 0 up, 1 down | Aug 7, 2025 | $52.44M |
| Mar 31, 2025 | $0.06 | -$0.02 | N/A | +400.00% | Beat | N/A | 2 | 0 up, 0 down | May 8, 2025 | $46.01M |
| Dec 31, 2024 | $0.43 | $0.14 | $0.13 - $0.15 | +207.14% | Beat | +65.4% | 2 | 1 up, 0 down | Feb 27, 2025 | $59.08M |
| Sep 30, 2024 | $0.45 | $0.38 | $0.31 - $0.41 | +18.42% | Beat | +164.7% | 3 | 1 up, 0 down | Nov 7, 2024 | $80.54M |
| Jun 30, 2024 | -$0.05 | -$0.10 | -$0.19 - -$0.08 | +50.00% | Beat | -150.0% | 3 | 0 up, 1 down | Aug 1, 2024 | $47.08M |
| Mar 31, 2024 | -$0.05 | -$0.15 | N/A | +66.67% | Beat | -155.6% | 3 | 0 up, 0 down | May 2, 2024 | $43.77M |
| Dec 31, 2023 | $0.26 | $0.30 | $0.27 - $0.35 | -13.33% | Miss | N/A | 3 | 0 up, 0 down | Feb 29, 2024 | $72.18M |
| Sep 30, 2023 | $0.17 | $0.14 | N/A | +21.43% | Beat | +240.0% | 3 | 0 up, 0 down | Nov 2, 2023 | $56.12M |
| Jun 30, 2023 | $0.10 | $0.07 | N/A | +42.86% | Beat | -64.3% | 4 | 0 up, 0 down | Aug 3, 2023 | $54.57M |
| Mar 31, 2023 | $0.09 | -$0.01 | N/A | +1000.00% | Beat | N/A | 3 | 1 up, 0 down | May 4, 2023 | $52.77M |
| Dec 31, 2022 | -$0.12 | $0.01 | -$0.08 - $0.05 | N/A | N/A | -220.0% | 3 | 0 up, 0 down | Mar 2, 2023 | $58.64M |
| Sep 30, 2022 | $0.05 | $0.03 | N/A | +66.67% | Beat | N/A | 3 | 1 up, 0 down | Nov 3, 2022 | $57.10M |
| Jun 30, 2022 | $0.28 | $0.09 | N/A | +211.11% | Beat | -12.5% | N/A | 0 up, 0 down | Aug 4, 2022 | $59.52M |
| Mar 31, 2022 | -$0.01 | -$0.11 | N/A | +90.91% | Beat | -101.8% | 5 | 1 up, 0 down | May 5, 2022 | $45.74M |
| Dec 31, 2021 | $0.10 | -$0.09 | -$0.22 - $0.19 | +211.11% | Beat | N/A | 5 | 0 up, 0 down | Mar 3, 2022 | $55.36M |
| Sep 30, 2021 | -$0.99 | -$0.22 | -$0.51 - -$0.18 | -350.00% | Miss | N/A | 6 | N/A | Nov 4, 2021 | $46.24M |
| Jun 30, 2021 | $0.32 | -$0.14 | -$0.40 - $0.01 | +328.57% | Beat | -8.6% | 7 | N/A | Aug 5, 2021 | $53.38M |
| Mar 31, 2021 | $0.55 | $0.34 | -$0.79 - $0.39 | +61.76% | Beat | N/A | 7 | N/A | May 6, 2021 | $98.17M |
| Dec 31, 2020 | -$0.38 | -$0.31 | -$0.71 - $0.19 | -22.58% | Miss | -3900.0% | 9 | N/A | Feb 25, 2021 | $52.56M |
| Sep 30, 2020 | -$0.60 | -$0.14 | N/A | -328.57% | Miss | N/A | 10 | N/A | Nov 5, 2020 | $50.75M |
| Jun 30, 2020 | $0.35 | $0.14 | -$0.53 - $0.16 | +150.00% | Beat | N/A | 11 | N/A | Aug 6, 2020 | $70.58M |
| Mar 31, 2020 | -$0.20 | -$0.68 | -$0.97 - -$0.42 | +70.59% | Beat | -200.0% | 10 | N/A | May 7, 2020 | $51.22M |
| Dec 31, 2019 | $0.01 | -$0.26 | N/A | +103.85% | Beat | N/A | 10 | N/A | Feb 20, 2020 | $9.00M |
| Sep 30, 2019 | -$0.12 | -$0.45 | N/A | +73.33% | Beat | -175.0% | 9 | N/A | Nov 6, 2019 | $56.35M |
| Jun 30, 2019 | -$0.57 | -$0.89 | -$1.37 - -$0.74 | +35.96% | Beat | N/A | 9 | N/A | Aug 8, 2019 | $107.84M |
| Mar 31, 2019 | $0.20 | -$0.20 | N/A | +200.00% | Beat | +900.0% | 9 | N/A | May 9, 2019 | $99.07M |
| Dec 31, 2018 | -$0.80 | -$0.77 | -$1.02 - -$0.50 | -3.90% | Miss | N/A | 9 | N/A | Feb 28, 2019 | $71.08M |
| Sep 30, 2018 | $0.16 | -$0.45 | N/A | +135.56% | Beat | N/A | 8 | N/A | Nov 1, 2018 | $62.63M |
| Jun 30, 2018 | -$0.59 | -$0.82 | N/A | +28.05% | Beat | N/A | 5 | N/A | Aug 9, 2018 | $50.77M |
| Mar 31, 2018 | $0.02 | -$0.31 | -$1.77 - -$0.31 | +106.45% | Beat | N/A | 6 | N/A | May 9, 2018 | $66.52M |
| Dec 31, 2017 | -$1.71 | -$1.97 | -$2.25 - -$1.65 | +13.20% | Beat | N/A | 7 | N/A | Mar 1, 2018 | $21.61M |
| Sep 30, 2017 | -$1.36 | -$1.42 | N/A | +4.23% | Beat | N/A | 7 | N/A | Nov 9, 2017 | $6.08M |
| Jun 30, 2017 | -$1.38 | -$1.31 | N/A | -5.34% | Miss | N/A | 7 | N/A | Aug 9, 2017 | N/A |
| Mar 31, 2017 | -$1.16 | -$1.20 | N/A | +3.33% | Beat | N/A | N/A | N/A | May 10, 2017 | N/A |
| Dec 31, 2016 | -$2.04 | -$1.92 | N/A | -6.25% | Miss | N/A | N/A | N/A | Mar 1, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.65, down 16.7% from the year before. It was -$5.60 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.65 | -16.7% |
| Dec 31, 2024 | $0.78 | +25.8% |
| Dec 31, 2023 | $0.62 | +210.0% |
| Dec 31, 2022 | $0.20 | N/A |
| Dec 31, 2021 | -$0.02 | N/A |
| Dec 31, 2020 | -$0.83 | N/A |
| Dec 31, 2019 | -$0.48 | N/A |
| Dec 31, 2018 | -$1.21 | N/A |
| Dec 31, 2017 | -$5.61 | N/A |
| Dec 31, 2016 | -$5.60 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,800 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,775 | 6 | |
| 2026Q2 | Jun 30, 2026 | 4,227 | 7 | |
| 2026Q1 | Mar 31, 2026 | 8,286 | 7 | |
| 2025Q4 | Dec 31, 2025 | 4,417 | 7 | |
| 2025Q3 | Sep 30, 2025 | 4,602 | 7 | |
| 2025Q2 | Jun 30, 2025 | 4,565 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,227 | 9 | |
| 2024Q3 | Sep 30, 2024 | 5,427 | 8 |
2026Q3 Earnings Call
Opening remarks
Mariann Ohanesian Senior Director of Investor Relations Thank you, Latanya. Good afternoon, and welcome to Puma's conference call to discuss our earnings results for the third quarter of 2026. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President, and Chairman of the Board of Puma Biotechnology; Maximo Nougues, Chief Financial Officer; Heather Blaber, Senior Vice President of Marketing; and Roger Storms, Senior Vice President of Sales. After the close today, Puma issued a news release detailing earnings results for the third quarter of 2026. That news release, the slides that Roger will refer to, and a webcast of this call are accessible via the homepage and Investor section of our website at pumabiotechnology.com. The webcast and presentation slides will be archived on our website and available for replay for the next 90 days. Today's conference call will include statements about Puma's future expectations, plans, and prospects that constitute forward-looking statements for purposes of federal securities laws. Such statements are subject to risks and uncertainties, and actual events and results may differ from those expressed in these forward-looking statements. For a full discussion of these risks and uncertainties, please review our periodic and current reports filed with the SEC from time to time, including our annual report on Form 10-K for the year ended December 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this live conference call, November 5, 2026. Puma undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, we may refer to certain non-GAAP financial measures that involve adjustments to our GAAP figures. We believe these non-GAAP metrics may be useful to investors as a supplement to, but not a substitute for, our GAAP financial measures. Please refer to our third quarter 2026 earnings release for a reconciliation of our GAAP to non-GAAP results. I will now turn the call over to Alan.
Alan Auerbach CEO, President, and Chairman of the Board Thank you, Mariann, and thank you all for joining our call today. Today, Puma reported total revenue for the third quarter of 2026 of $55.1 million. Total revenue includes product revenue net, which consists entirely of NERLYNX sales, as well as royalties from our sub-licensees. Product revenue net was $54.1 million in the third quarter of 2026, an increase from $53.6 million reported in Q2 2026 and $51.9 million reported in Q3 2025. As a reminder to investors, Puma reported NERLYNX sales includes both U.S. net sales of NERLYNX and product supply revenues of NERLYNX to Puma's ex-U.S. partners.
Frequently Asked Questions About PBYI
When is Puma Biotechnology's next earnings date?
Puma Biotechnology's next earnings report is expected for Feb 24, 2027.
Did PBYI beat earnings estimates last quarter?
Yes. Puma Biotechnology reported EPS of $0.11 for the quarter ended Sep 30, 2026, above the $0.06 estimate, a 83.33% surprise.
What EPS do analysts expect from PBYI next quarter?
The consensus EPS estimate for Puma Biotechnology for the quarter ending Dec 31, 2026 is $0.23 from 3 analysts, with estimates from $0.23 to $0.24.
How often does PBYI beat earnings estimates?
Puma Biotechnology beat the EPS estimate in each of the last 11 quarters, with an average surprise of +116.51%.
PBYI pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors